Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Kymera Therapeutics Quarterly Conference Call. Leading the call from management are Nello Mainolfi, Founder and CEO; Jared Gollob, Chief Medical Officer; and Bruce Jacobs, Chief Financial Officer. [Operator Instructions]

Before we get started, I would like to remind everyone that some of the comments that management make on this call include forward-looking statements as outlined in the press release. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in Kymera's most recent filings with the SEC and any other future filings that the company may make with the SEC.

to Kymera undue update disclaims not forward-looking on such cautioned and statements any are place reliance any these statements. You obligation to

Founder, now and will hand call Nello I the CEO. Mainolfi, to President

Nello Mainolfi

very the fully and our thank mission to company. the for today. with Thank you, integrated and medicine excited made how you, share over Operator to we've achieving best-in-class, global quarter joining degrader to everybody, us building We're last progress contributes you it

portion share, Jared of study which his cohort KT-XXX more recently Phase I process trial patient We with completed, completed in clinical and our XXXX. concludes the December in campaign the always of a with I publicly the to the details as currently but remarks company we for will the collecting as Phase we're data the data on and all we this the drug. of partner, share of subsequently the analyzing the data XX, Sanofi. And will on webcast our announced, We do, analysis the data. share plan morning

demonstrated is objective with reiterated safety MAD patients the confirm HS the AD past, that patient the in in in the volunteers the we have SAD and is As PK/PD cohort was in and what healthy cohorts. of with to consistent and

the we XX call. plan month, on to on we oncology announced pipeline December last our As update investors clinical also

and IRAKIMiD our to As KT-XXX we enter I programs, is soon X X KT-XXX clinic which KT-XXX. MDMX STATX believe program you know, we the all and clinical-stage degrader that expect have

of escalating they're ongoing both respect portion. and dose KT-XXX I Phase the -XXX, to With our stages trials, the in

the for as an share which Aiolos, go we demonstrate and a mechanism dose the proof into Again, reminder, even is a Ikaros interest safety IRAKX ability obviously the and to advanceable this which we will more early the we is for call with is as degrade here of call. substrates XXX objective to what proteins of As cohort XXX define profile. STATX and Jared in

through to the an financing placement our additional continue future. share continue we in a our we raised sustainable Kymera's their discovery Along $XXX with aligned our have way work clinical by team. long to really private this progress, term-oriented was build to and team group in invest end, platform To that the program, led which ensure confidence August, investors, committed, of we equity million in of each a clinical to our and which broad pipeline, company in in strategically demonstrated and a resources optimism and

we result, As a in a million ended cash. in position, the third approximately $XXX very quarter financial solid with

the wanted the Before recognize to to our change Jared, a Board moment on of call over I Directors. we take to I today announced turn also

Kymera say, me a position both biotech have of well heard fully to started many PPD you a build leadership and company integrated As as into in have biotech. we in to as sustain

and knowledge As Board requisite base we obviously to build that as mission, will a employee to our achieve both an support success. Directors bring experiences all we work as continue of this to well the

Dr. pleased that that to we're end, Victor Directors. joined To of has Board announce our Sandor

BioPharma know recently had lives the global medicines an Pfizer industry. acquisition most of at by was clinical prior significantly career and development in has have its He that expertise biopharmaceutical oncology. those he who Victor, you has to in in impacted For patients, deep don't of CMO especially impressive Array the of

thankful over the for is been all important having growth We're very an X has our after another recognize contributor to just wish best. important having and X I and at Nicholson, the Don to company's served started will leaving Kymera's Importantly, like also his past one years for him would thank directors be Don who and of after contributions shortly success time, and Kymera formation. years. as director, of the same and the director the longest-tenured last

of that call recent will With Bruce each a our in Bruce over programs before myself disclosed handing said, remarks for in greater will before the call be our financial back to finish which Q&A the the turning some Jared available. will cover details for for then progress update. Jared? operator now I Jared, concluding session to and with a

Jared Gollob

IRAKX share a IRAKX, a Thanks, first-in-class is updates oral clinical potentially excited degrader protein begin I'll on our to developed suppurativa, key in involved atopic our I'm such Nello. being X for inflammation, program. receptors potentially IL-X dermatitis the programs. receptors. the TLR/IL-XR-driven with of mediated KT-XXX KT-XXX toll-like inflammatory of others. and activation treatment is immune diseases, by of hidradenitis in as

you As days, an for patients administered an is study daily basis KT-XXX, C Day open-label of outpatient with through recall, may on Part XX. followed XX

the As in cohort, our KT-XXX. dosing we shared last completed month, Phase C for patient we've or I trial Part of

SAD dose disease-relevant demonstrated robust favorable IRAKX we of vivo all ex that and the single in dose the safety near-complete and last MAD their visit, patient of the over have I or The portions ascending C patients multiple XX profile. Phase Day Additionally, degradation of peripheral cytokines dosing inhibition Part followed blood cohort cells multiple ascending the healthy study. we stimulated skin, confirm trial. and In in the volunteers mononuclear completed today studies, a and of can XXX

per that approximately the to dose with of This MAD inhibition pharmacodynamics either or and [indiscernible] ex disease-relevant is moderate includes state healthy day while equivalent also signs and cytokine expected plasma with early the dose clinical to a of Patients dose the and activity. pharmacokinetics C exploring showed examining severe Part daily of fastest which in portion blood is maximal hidradenitis in XXX-milligram milligrams vivo. suppurativa and broad or a volunteers maximal in in of dermatitis of that KT-XXX, to XX received to the a is in trial the skin safety, degradation achieved provide patients state. close atopic KT-XXX exposure

that profile in safety and our to in goal patients the mentioned, line previously volunteers. study is in seen have what As we for PK/PD this with is confirm healthy

KT-XXX the and plan we plasma IRAKX December, in gene well share of biomarkers on co-inflammatory in transcripts on in as inflammation. skin In skin on levels the of AD active to data and PBMC lesions and of expression lesions as the HS impact on

undertaking inflammatory also assessment disease HS. for an impact HS; AD well scores endpoints, are of EASI, early assessments symptom and We both global counts exploratory as Area AD; or of on severity and and and clinical as for Index, Severity [indiscernible] Eczema including for nodule

should which past, expect to open-label small one a have the do we an it's As important without noted number we placebo, viewed until not IRAKX dosing consider the through the steady-state data lens. study, skin second signs of clinical in the be result, patients as in reach this a and half of in early X-week is in degradation that to period. activity that of And on

And our few be tolerability We reminder, in Part studies, C. and following mild adverse adverse as in a events. to serious safety and KT-XXX MAD only SAD no and moderate a demonstrated will also events

will out after is show multi December the self-limited; non-adverse whether that update but this include plateaued case, dosing to we continued evidence observed including days volunteers safety a analysis, that to that with healthy [indiscernible] X it Our days. modest in in XX prolongation QTC

X our I oncology stage the update of dose everyone Before of which are will ongoing STATX, on Phase and trials. MDMX escalation our the includes remarks, pipeline which IRAKIMiD their I I disclosed first conclude in my degraders,

webcast As on an mentioned, update our December will pipeline. include our

a quick has cancers linked numerous other reminder, autoimmune is diseases. been transcriptional STATX that inflammatory As a to regulator and and

KT-XXX's malignancies Our evaluating tumors. Phase and solid hematological I in clinical potential trial is

lymphomas tolerability, in safety, and patients the evaluating PK/PD KTE-XXX is trial tumors. the solid Specifically, adult in activity and/or of relapsed refractory clinical with

stage We before second patient other lymphoma, across peripheral tumors. T-cell order to expansion trial combination to and reach and where agents. Phase granular either then safety, a antitumor refractory liquid characterize soon monotherapy KT-XXX of and/or of leukemia focusing X on in Ib The been lymphoma, populations in or solid we further cohorts with broadly pharmacologically recruiting possible expect relapsed solid Ia dose doses large to clinical PK/PD in Phase active have as as escalation T-cell will consist see tumors cutaneous in lymphocytic activity, and as tolerability, in the activity the

Food its treatment drug for the the designation orphan this T-cell lymphoma, September, its following earlier second KT-XXX drug for U.S. peripheral Administration Drug lymphoma T-cell was granted cutaneous year. In orphan and of by designation

and KT-XXX, IRAKIMiD broaden program, heterobifunctional IMiD small single non-Hodgkin's lymphomas. is substrates the IRAKX in in Our a and interferon relapsed against malignancies. cell STATX IL-XR/TLR stage activity is with and trial synergistically a both B on of with I to the to the Ikaros Phase and pathways currently clinical the safety, dose B novel timeline Aiolos activity was as both KT-XXX address and degradation and/or designed refractory tolerability, targets cell type X degrader PK/PD patients MYDXX-mutant the KT-XXX KT-XXX of that similar the a escalation molecule. evaluating of is

for are will on Phase activity. most KT-XXX Similar to which I, population substantial lymphoma broad patients just we the described strategy the whom see we after clinical the enrolling with B expect focus of patients, cell to we a I

DLBCL. Phase expansion MYDXX-mutant cohorts MYDXX in Specifically, the in antitumor second Ib safety, to characterize further relapsed/refractory consist KT-XXX wild-type will and tolerability, stage of and of X activity DLBCL PK/PD

and a the XX% KT-XXX, forward MDMX remains of pXX in functioning malignancies been tumors look suppress more MDMX MDMX potent highly tumor year-end. to small Kymera by track pXX. degrader completed the updating and the unlike on be regulator is is exposures. ability common even brief our on IND a and of loop We a to apoptosis, cancers. most to which range of the rapidly has hematological is in potential molecule Finally, pipeline shown wide feedback developing with achieve has crucial investors degrader, in preclinically to clearance than studies or KT-XXX MDMX that, IND-enabling suppressor, wild-type our effective inhibitors, have December. has induce to solid with intact

financial I for will Jacobs, call Chief brief quarter. first now on our the Officer, Financial the some comments Bruce our share to will Bruce? results hand who

Bruce Jacobs

Jared. Thanks,

recognized Vertex approximately sheet we the reflects $X.X milestones. million. was partnership receipt That we For of recognized quarter, a revenue any over collaborations. and several revenue, Sanofi deferred end total the our of recognize million the the to future the to the expect on revenue $XX reflects potential the quarter, At excluding total pursuant revenue our of years, that balance next

The spending million, decrease the $X.X from June comp. a adjusted $XX G&A the million the noncash stock-based the to comparable comp, adjusted comp. quarter for With a the was that $XX.X which amount stock-based of cash quarter. excluding for stock-based cash $X.X increase quarter. With reflects spend it X% respect spend in comp, again G&A to represented stock-based noncash excludes R&D million $XX.X X% again was million, expenses, in June million. million the reflects amount of $X.X represented That respect of from R&D operating quarter, comparable of About the which

the have exited quarter achieved. that million. in We and Recall runway yet any payments approximately $XXX balance not cash we a of that second cash not with from do include equivalents our we milestones

for guidance runway plan the incorporates of particular, driven least pipe around into completion XXXX the the to financing, guidance, runway of the of extent closer cash do to our runway update specifics this we at year-end. $XXX but in Our by million extension

With that, concluding I'll remarks. for turn the back to Nello some call

Nello Mainolfi

Jared. Bruce Thanks, and

As we can patients. look science webcast, transitioned action in that December Kymera we a one observe our to which forward it's on into in providing has successfully update new phase, a clear our in clinical

medicines. our are excited of immunological of assess may finally to patients platform conditions that and over have to programs the in the and with X demonstrate cancer traditional impact advantages We begin to our

With all the getting made we're started. this progress quarter, just

clear our several and In clear this IND MDMX degrader programs, year rationale clinical significant degrader, and addition to to programs on an we're advancing KT-XXX, track earlier opportunities. with our we're commercial X for

place opportunities best-in-class in Vertex to recent our discovery with Sanofi, pipeline engine. with and partnerships to an productive maximize potential the with platform of continue maintain investment financing, the and of we So array our

team to I questions. our Kymera your like well this patients as look in as finally, I'd point, call to for you all of the participating partners, this who At forward and trials thank are and, our clinical in the participating

you again. I microphone back will can your we questions. take operator the Thank the now to so hand

Operator

the [Operator of from line first comes question Stifel. Your Brad Instructions] from Canino

Brad Canino

the us include deliver I X want Day to based package will expect data Or date to go First, back Nello, you be then, your will in Sanofi R&D weeks year. follow-up? XX-day you've extra package of XX when data cut? tell And it to the And to set relation that last the to on you December can the up?

in decision suite ligase-enabled the EX ambitious share ligase the which status points an set program EX critical included You first update for target remaining us for comments development. that XXXX of tissue-restricted, in you Can any on candidate? the goals just selection and first regarding that perhaps for

Nello Mainolfi

Two Brad. Thanks, Great. great questions.

a one time. So at

plan data the deliver to So Sanofi the complete to we package. first so one,

obviously, of the observation. period X of the follow-up extra that will also So include weeks

have think as I saying today on completed clinicaltrial.gov, also that phase it's the we and that we're well.

the So the when and every also gone today, said we X analyzing mean we follow-up. we're of study patient weeks completed, that that has data. through say we've collecting still is What also

So of not collection yet. phase data completed the is

As the of that totality our soon the with we as complete partner. will we share phase, data

haven't had will would that team. relationship with a said because, be happen all internally. we're we Maybe haven't add, we the only thing when work doing and always we've the to honest, close very the that So Sanofi communication I completed

things. we as collecting make and possible we're data as that share to meaningful be collect we as try in still we helpful sure So when also time this anything

are programs in of those preclinical use ligase has close will of us entering to the a dose-limiting toxicity EX programs an to stage, which preclinical well-known entails To restricted target. as development. body several the of a I the your of oncology second the actually many And have we in one overcome expression actually that said, that question, allow

Maybe haven't some which of point are. our them, update X provide are. firmed of next year on X yet, we'll see or although we I those is plan, up to think stage they where We'll on depending at disclose. development it an programs

as say So shared I not guess be satisfying it's information stay that. but will super I'd tuned, on more

Operator

comes question from the Sachs. next line Shibutani Your of from Chris Goldman

Chris Shibutani

you can they'll different that may way scenarios you've one we programs, opportunity your does from could Sanofi that proceed hear Sanofi oncology. or scientific relationship helpful. of KT-XXX, that is premise the pursue outside play in as clear be that well? be out, for both with that the them in and decision that they to would of we that would there optionality that how have explore that? And the make, frame thinking Just terms the for pursuing any Just be there? And Would would with indications there secondly, Any on sequentially, terms of the structured partnerships? to so

Nello Mainolfi

I'm your line the you one the X can understood if second, Chris, you on I can programs? not you question, said question. more first when for stay sure clarify fully

Chris Shibutani

the for HS. Just thinking and about X indications AD

so binary of we be clarifying set. is but that option that decision there's sort singular And and thinking perhaps the that shouldn't an from Sanofi

Nello Mainolfi

I missed Sorry, Chris. that.

So thank you.

question this in have on the contract. IRAKX know, to are We Sanofi here best, this And data we'll a but to drug to of both back outside partnership if So we're believe potential variety ambitions. has wide the our what to be you going diseases. and Kymera beliefs that one, in generate with mechanism have Obviously, and then, so That's oncology molecule degraders small as we anti-inflammatory doing. not immunology. of that's the large the actually spirit Sanofi of support

development, to decision will it, the make into, late invest global when a development drug. KT-XXX it's transition, when transition, the call if to we make to decision the into of the Sanofi So and decision

indication-based it's in the late it's but development. not so And

immunology we've at Kymera company partnership, is be use clinical the in to And they that number always they to reason for has that world. view, and from say and of built Sanofi footprint immunology. Kymera to the partner publicly, and least a broad commercial want been the one from point as benefit the We, benefit, both as aligned Sanofi in

prioritize global say always indications. several how And indications. obviously, development so been decision is at to decide and the But would collaboration like to with pursue Sanofi multiple forward. to of hope, I we But then their in we data of, the the has indications, spirit be try going would look to and

oncology. of STATX, outside

So couple something in as strategy talking up think we for about data data of released we'll program I have years. this very And a different asset. conferences. We've of This clinical kind this our on. is we around been we're some firm keen share

any But or go any For in partner. different tell now, is things independently this obviously, new time if Kymera other from leading something is that will existing ways. potential

Operator

Rao comes from Company. the question of next Your & from line Divya Cowen

Divya Rao

on Divya for is Mark. This

on and one program one KT-XXX. on then have the We oncology

analysis the see you of And And what are quarter? can I now C what for just R&D to remind Part us that data is degradation then data-wise at this would programs, some is but that that expect presenting completed, So before the know you for and the doing translate into generated still to to package still XXX, level guys we the Day? needs ongoing anything else could to activity? clinical then expect oncology there be you data with Sanofi

Nello Mainolfi

to you do the oncology question? Jared, want Great. take

Jared Gollob

Sure.

to for hopefully proof tolerated. knockdown For doses call well us able is accomplish can are is the a is knockdown to be which and show what to of both to oncology we aim antitumor that intended level the preclinically safe associated with we targets at mechanism activity that show of programs, that that and

question knockdown Your target levels what around for the are various programs. of the

For in the we've Ikaros range in in sufficient DLBCL. the activity to the that knockdown us IRAKIMiD is and IRAKX Aiolos XX% substrates give IMiD of seen program, XX% MYDXX-mutated to

ultimately, level a program. like see that's of So we'd that, to in knockdown that

For to tumor days knockdown STATX, context. lymphomas in XX% induce greater maintained we've several regressions than shown in is that significant sufficient that also STATX-dependent for

R&D the benchmarks mechanism to and what able to ultimately safe through those hope we'll to see. enough from doses Day, of we'll that our that we'd tolerated. are sort the be initial But levels standpoint well at presenting be So are like will that show of dose be of at proof be

Nello Mainolfi

PK/PD it's advance able And PD, the to to And on transitioning want the maybe volunteers and patients healthy maybe thanks, and study good a I relationship from Phase of were both profile to question, is. that drug what safety maintain remind I'll to XXX. take to really opportunity purpose just to the demonstrate first, take the II. Jared, was into other the

And be between that -- that say, and strong that is in skin given will and that data inform to that now relationship a collect weren't disease-relevant, demonstrate PD that goal believe in results do defined, a able to means can we a that that that cytokines we that. our let's our now exposure [indiscernible] volunteers correlation, II new impact to or selection, so is actually PD has direct dose the create key blood Phase to degradation continues there into healthy PD chemokines on pathway-relevant

call it, that we between, correlation biomarker. and So say, the disease-relevant something as engagement is let's target

so I clinical don't completely, obviously said, it as also be trying And then, that a collecting we that we goal with establish dismiss just of we've to will said the endpoints potential correlation study. that that endpoints anything the the can size exploratory PD, tied biomarkers again with obviously highly clinical the be some would design be some to of or given and

back data. to actually sorry, we collecting are your going question, still Now

So especially can that And data there open-label some weeks then that imagine regards is data, is to generate. with to is there in accessible you study. some actually takes PD, easily an

are So we data. not data. We're generating just analyzing

so totality more of would the wanted the Sanofi December only then data fully having of to data. reason take approval sharing the again, before And it, all the both their time we to that's because with And the have share to you. it us in collect call, all for and with a get hand to data

Operator

of from question Joseph Eric JPMorgan. from the line next Your comes

Joseph Eric

you And guess, talk at data evaluating specifically every-other-day dosing. the Joseph data December healthy perhaps specifically just biweekly guess, data know or the you for JPMorgan. XX? be I presented about I volunteers. that data cohort rationale of XXX? assuming added at is dosing those Eric that expect should with gathering additional the Nello, It's you're I can to in regimen gathering? we that then, Is And this looking that from additional the intermittent you're I'm some

Nello Mainolfi

for Thanks, up, Eric, that actually. bringing

mean, generating taking to a time first And and the are can answer to is There takes the we're cohort. all read I it has initial as that past, patient quickly. is focused cleanup lock and transparent, be in clinical data question on endpoint in even what These longer, maybe a that. I So said, more as and you the safety on no. your is PD the study not and do simple this biomarker data. get is it even obviously to assays. does done as And just

Jared in designing work that the his done And things other In in have I HS are fact, these in hopefully and what eventually I for have doing doing we're the and don't and they've companies done all patients. industry. generating to the ever team actually executing AD that we're and cutting-edge believe thank data.

a dosing, Sanofi, was infrequent the to where past, as to in to to the extended With the for we wanted clinical experiment dose. wanted ability transition just run a KT-XXX PK/PD in the study regards not that we lose a to we this before run of given that studies. will single the learn we that eventual program said was has And learned learning, the degradation that SAD I've after this

it don't dosing wanted frequently. less our to I us, disclosure. platform be we and of will would big far learn it So question. reliable But be how how also a expect was that part for that But

be we'll hopefully that to be informing program is on think of be and patient to there I development the but focused the anything data further how the on relevant we'll will development. that -- unless focused

Joseph Eric

sort I oncology of Okay, could, just I Maybe setting... for follow-up, programs. a And on thanks that. great. the if appreciate

Nello Mainolfi

We can't hear.

Joseph Eric

me. Excuse

a oncology Just of dose. the do thanks a whether I'm XX. XXX? on part XXX point framing line and cohorts might the be presentation expansion of just you for you sight start on you might and detail programs Really, when for can have the wondering how you as where enrolling at into close Phase a follow-up expectations II December recommended

Nello Mainolfi

this -- to it's all, it's point, appropriate at of for first think probably not comment. us I

is would we're I phase it. might say the we're on in So December. we focused dose and escalation But this on still comment what in

where prediction and different a of the It to development where any a the your you here clinical step is you it at versus are degradation to completely you if beauty way. know do need you allows in maybe right, you're just a reason or this of to do take to of expectation for. in us efficacy or many them data-driven why design drug trials, So because your versus your of data-driven back, that allows your do what drug you are looking the type technology you of development point expectations kind given achieve

of So MPD we escalating expectations an where level ability instead and have needed an achieve we of to efficacy. escalation, [ph], blindly to have we the that our degradation opportunity in on versus dose escalate to learning are

And will drugs. the the success of known with will we it let's for is really both reliable, that line oncology. see predictable and of the in I can right where drugs with PK/PDs, show the as really if way mechanisms and KT-XXX, translation program, getting say, oncology Because case, have in these event goal that the goes clinical think Because the be to bullish are of the a and So in seen that, for think this we year is potential large these really protein this forward. if prospect the we preclinically. we've and good a here seen is what in moving as is on of we've the safety the the I degradation dose-responsive degrade if profile well PD with safety derisking

your want I Now don't to question. dismiss

December. both will year to that will time continue comment I on and suspect do we think the I next escalation we more at some in expansion but maybe that we will some discuss there

Operator

the Morgan Vikram from from line Stanley. comes question Purohit of next Your

Vikram Purohit

what these steady-state exploratory the until that back for more be? be could to done the then there KT-XXX, reported and earlier have might prepared on more Following any if you Part learned up the second that work there's healthy And had the mentioned to I here half communicate won't out been wanted secondly, update data if on interval findings the with QTC rationale you the so, you going volunteer of degradation anything set? on in program, your you see C. same signals versus if dosing just any on And update seeing prior on palpitation your mechanistic to remarks,

XX-day sets that, given efficacy space? that some available people advise to here this data you interpret So data other in how would versus are the dermatology

Nello Mainolfi

want I on that of our Maybe, between draw on a Jared let first the before palpitation Jared, to mechanism, comment on QT. will thing on we say on anything Vikram. to correlation if the Thanks, Great. never we want understanding maybe The and QT comment Jared, to at the only else you line of passing question. least. But have share I'll it

Jared Gollob

steady we've current dose- period sort XX right, effect Day to that days. not, think and on of the a anyway, effect exposure-dependent that we cardiomyocytes of effect the clinic, vitro then until at of the in to have in or been previously, consistent effect dosing mild described on that where what somewhat concentrations end our I we high the and delayed herd is based remain of with in an clinic saw with data, able with the we that's have a that's appears is iPSC plateau after see X delayed that is sort and consistent

of new on of we to report those have so terms really don't going on. what's our anything And understanding in mechanistically lines

sort see this sort B. if impact, effect. think what QT a any, is of there in of saw that is really that observe to do we as further clinical that -- out we now to inform what plateauing us days C XX Part us XX will will important And to as non-adverse QT that continue we in of I for continue subclinical past in did think Part days Part effect I be we to to of B, dosing, of

Nello Mainolfi

kind on expecting this compare to And the small take kind efficacy other very short say I and different differences mechanism, eventual placebo for possible this that is, given is and we how time. to to in set say what able maybe of changes, for pathway, difficult But not that data between to with or clear and purpose study the continue to to terms of again, relatively again I and way readout we'll you is us in PD And we've see mean, of any if get efficacy AD and of really hard, one the it clinical why really a HS drug to to think, work would the just a of new to different new for that we It it's if there scientifically us think no the generate what trends study. mechanism, do, from because data agents, the other really numbers, endpoints. have the study. on be biomarker to works then question be question, studies, see the if see, want based back we I in this and unfair the for any or study other is early designed you asked signs a is doesn't and, impossible, comparison are

Operator

question of UBS comes the Financial. line from from next Eli Merle Your

Eli Merle

maybe data might and could timeline, expansion how like on elaborate be on planned what thinking looking the of in MDMX, also just about if we year. could, the initial best On dose this about any that cohorts had types most clearance, suited for in look you would say, sense you're next as data on initial potential if tumor be trial and what would design a make biology, you then thinking terms see at. and you assuming escalation IND commentary just And

Nello Mainolfi

talking enjoy I programs Eli. our Thanks, other in about also pipeline.

to it's -- we've be think another others program. that Obviously, that we that things for can or but more MDMX, not technologies demonstrate do. other this used do about excited less I have built to cannot this program than So technology really we're really

you'll that our our been programs so true. that target stage good everybody a hopefully, that X time. selection in be And that next really preclinically, we the in And disclose appreciates to when all philosophy terms continues see X, are philosophy has of

So biological different with molecule. a molecule is absence super not high small is of is at the with that a pathway looking just genetics in MDMX, what that This eventually generates small is this wild-type to level intervention has seen that which not finally pXX tumors shows MDMX inhibitors. sensitivity of that and replicate data been

to feedback apoptosis not we is in we one and way the we a do to we we're molecules are as cell to that protein way do. said, And the small overcome because this able quickly, drive able loop that remove

design, a the a haven't can several you this focus I'll Jared high-level allows more we response And is in but mechanism. overview. have both say, what today something that strategy response. he us which on believe to clinical will is apoptotic see our will very one maximize be is a.m., indications solid highlighting maybe would AML of work that I on we But indications have And I of on rapid indications I what that safety our comment a to trial tumors ASH let So and although disclosed tumors where we out, fully at say it's believe, there this type bit the abstract liquid of give for and X:XX I interest. efficacy

give overview? maybe want you high just do to Jared, level a

Jared Gollob

Definitely.

sort to action Just that opposed and we're just as of molecule just mechanism degrading give a of intermittently. a reminder unique as able dose of high-level of to overview because the inhibition, to small

be intermittent escalation, Phase into an the it dose the in followed I. Ia bringing dosing, on Ia. in on design, Ia tumors, and standard Phase planning malignancies Phase malignancies interest, IV a Ib in and Phase a up trial will heme safety, both sort have we're be But IV dosing, tumors. both heme of within And in able PD by we solid understand importantly, the of to expansion. so solid tolerability as Phase will opportunities So to And us will infrequent to indications as well set particular put

Ib dose as lymphoma, up Phase in expansion bring a including but will then tumors. in well come likely dose especially as AML a we into solid with that And involve do potentially II malignancies, others, Phase or then then tolerated eventually, recommended to expansion, once maximum that

Operator

comes of question Geoff from next of Meacham Bank America. from line the Your

Unidentified Analyst

on [ph] you provide a Geoff between Joe is are selection and achieve you can This any tumors? for Meacham. tumor-agnostic patient label? liquid and And your information solid breakdown KT-XXX, On on additional to hoping

Nello Mainolfi

identifying that question. hopefully to comment know we something to development Joe, But team that also are on, able of to year. not meetings, meetings comment ongoing get our working We is. that and translational are. not this right our obviously, and the that's rest specifics tumor-agnostic the being type I potentially is strategy in to assured on right is And is we to one data at discuss a position works, of share generating we're what next now to great approval. but to different the where on unfortunately hope medical the translational in the position start

Operator

Your next question Rich comes from from of Law line the Credit Suisse.

Rich Law

also data X Can a ongoing? you And data that and you yet Grade seen you saw place can earlier we was stopping safety all data piece-wise for of follow-up that or question And Sanofi study you preparing data hasn't the they or are Part in no Can is still C? mentioned the when real-time effects? confirm comment rules was any on there rule X Sanofi. that adverse what already were Grade for the that out

Nello Mainolfi

the was Ah. first part? What

the the we regards past, think have there we were I share in we them. obviously shared can we've in position have as been them. Obviously, you communication, we're can't So said comment in share earlier, that study's constant we've specifics. But haven't to I with events With assume it on throughout again, we the really collaboration. success, not to said would or if the that impacted had to are as the really Sanofi, what

at it that. leave I'll So,

Operator

comes Your next of Schmidt Guggenheim. Michael question line from the from

Michael Schmidt

related us. which looking the that PD On program, other other target? degradation validate is there than target Just a this at you're couple study, from on I STATX are further KT-XXX markers could to potentially STATX any in your that Phase

Nello Mainolfi

you Michael. do that take want Jared, to Thanks, one?

Jared Gollob

Michael. question, the for Thanks

STATX, for best addition gene pathway. at at the have at are the STATX biopsies. at to look We'll at expression the opportunity We STATX looking looking either the tumor to yes, in profiles STATX in can on activation. serial also at that phospho-STATX So look or impact of impact actual looking we degradation looking pathway

to we higher So especially example, order those other where be clinical patient pathway, patients that see pathway or of target to these doing on an will hit bring to clinical all as start premutations target STAT target by but and also into to whether the We'll only that in responses correlate itself. patients affecting assess we opportunity can when to population, with can with the we the hitting we're get that the impact genotyping mutations us start give doses able for the can not show responses the T-cell we specific malignancies. at genotypes,

Nello Mainolfi

expect be not to So every Phase comprehensive study. patient. of global it's we do I a part something that of that a our kind of in can Obviously, assessment

Michael Schmidt

AML was perhaps particular, It you like myelosuppression. question as there And solid well. focusing Got program. then with wondering some class other I a your just then know in on tumors sounds degrader looking has are on it. All been the intermittent the toxicity; of I right. this And can drugs, around and degradation, with of MDMX mentioned And you're of some PD dosing class? think PK the drugs those you think just do have guess avoid that the I and that some and at, with mechanism given other associated I you in safety schedule been the issues on-target you

Nello Mainolfi

our that will we're of It's not as to said, we've just clarify, sharing AML is let's part indication. one obviously, generated Michael, main one strategy. of we interest, So the and just of -- clinical the say, indications data be of

much there than trick can have part and this second for editing more trying have very let's that's that do to effect your We safe case, really In that cannot want a to then and antibodies back or RNAis was the or say, a do agents. therapy, effective have you cannot again, use the is point do. before. to actually quickly question, Going make early I And of technologies your recovery. the molecules small things effective which, very on, with to protein question, degradation profound very, allow to molecules very the other gene or small at least

dosed mentioned Jared So infrequently. we

every enough to obviously And once dosed they're able sensitive recover apoptosis seen extremely tumor lead to that to cells that's X have cells. also see healthy and we to we we less cells cancer So weeks. being because rapid

And that part maximizing IRAKIMiD we're developing is theoretically, have extended infrequently. dosed the not a exactly can drugs allow so built exactly managing are be manage to at PD of way. designed similar, also these safety noncancer IMiD we've so These have In able and or is the with you are although efficacy. how with but our this we drugs dosing with cells. molecular a been level same recovery them the infrequently to that paradigm And that neutropenia how why way, we're philosophically, will to dose the

cancer degradation is the can drug how of show thoughtful immunology trying in can pushing very, to technology not through we're envelope using probably paradigm about affecting biology what the envelope development, push biology the on that you is So actually what very change just we're Kymera the think on doing tumor. at protein the in but one to

Operator

Shi Your next line of from question comes from Jefferies. Kelly the

Kelly Shi

regarding A rate out efficacy follow-up question of the XXX [indiscernible].

lines of other AD besides XXX [indiscernible] [indiscernible] patients, efficacy many how and trial complicate the drugs. for you and a prior had for to respectively? the expect DUPIXENT the interpretation, do any patients the allowed treatment to of also according to of other the further difference biologics So AD PK/PD prior actually protocol? or HS most and And compared And of HS

Jared Gollob

number actually question. Thanks not either type for did patients. We treatments AD restrict or or HS for prior the of

not I on therapy the had Part had had systemic If either the before biologics. C prior prior patients So who as prior as received any Phase a period patients allowed of received systemic coming therapies, required study. therapy, who or well received prior therapy they washout the to patients including

a clinical small do appropriate and probably endpoint of C, treatment. difficult That did would been along such we in to not characteristics not compounded baseline control of trying this Again, for we were efficacy with primary study. do prior didn't because So that. the necessary to have not allow because is the would study, our small feel is we That terms not concurrent a And to degrader. have results. therapy open-label it Part

do for we HS. However, treatments prior results, that either we results, what to keep AD at pay results, look we as attention the any when or patients And we course of were with the will endpoint interpret especially exploratory certainly will in of mind.

Nello Mainolfi

because previous previous we confirm, have not every they -- that have from to just so on we out. therapies therapies, patient, won't any impact do if were would we And Jared. washed know expect been Thanks,

they KT-XXX. there previous drug when will received on be so And no board

Operator

next SVB Kratky from Mike of from line Your question the comes Securities.

Mike Kratky

the Having are of can whether C, dosing Part AD those between with provide details number in expectations? the baseline split on patients any study the characteristics largely hidradenitis total in the and completed your portion you consistent versus

Nello Mainolfi

close mean, enough I not comment to this I to split. going at think point, just we're Well, the the we're on sharing data

we've characteristics, always severe, think said Jared, moderate baseline I right? I consistent. think that's to So

Operator

from Shu question comes from Zhiqiang final Berenberg. Your

Zhiqiang Shu

was set in potential I set, questions guess at would terms of second difference disease and your one, safety. wondering first these the And types prioritization if the on The us more December tell data in of be able you differentiate to between I point? the of biology X HS you provide AD. that And around then can about and the

should QT on prolongation less be oncology Given in that not any can And you frequent signal the expected? the IRAKIMiD, prolongation and MAD [indiscernible] safety QT, QT that you terms STATX comment finally, your for related schedule your also that you or been study, have change program, dosing also in on of worried can to in any confirm that, cohort? signal

Nello Mainolfi

Thanks.

And from first and I'll HS if maybe can [indiscernible] comment maybe, the start on Jared, the you biology. last. the So then

program, broadly. So anything the is last to easy. We that the platform don't one expect QT with has do

has compounded very impact, range in exposure this atypical clinical view, shared very, we've we we that again, in tissues believe this healthy have non-dose-responsive, within we leads no weak we [indiscernible] development in humans the a of QT volunteers. we've in that stays drug, for assuming prolongation it KT-XXX again, by seen on that said, that, our no cardiac impact is this [indiscernible] As the already, believe characterized to higher-than-expected as

cardiomyocytes, able said can in we take also assay demonstrated in even don't that we in change currents to I of that been change past degrader also particular shared we replicate Jared earlier we've the today IRAKX that it we've believe show We've said and another that and this that current.

So molecule-specific we it's event. know a

guess, little if I've Going and no sharing, is because study say is is all the expectation share. development sharing, I mean, discussed for is will will as KT-XXX. I an the from that worth there Again, for we again, December. why we we share of or never study on to there to have is worth guide advise, But we the had continue data past, low I is the reason out said there. in dosing this that back will will the safety, we've that infrequent almost impact anything be the the if It informative, that It platform. it informative of be the will drug. study will on it in expectations it

biology. to And on you Jared, if the on AD, want then comment HS and

Jared Gollob

Sure.

of shown of see a inflammation interesting diseases. mixed to in ThX, see AD that and been though of by biology, sort is is addition the terms cytokine as both multiple these diseases, is there In be the even is have can HS both In activates toll-like disease activation. and in actually reality, are the by ThX/ThXX receptors, family diseases. of some have Even members. ThX been importantly, in to as of analyses skin important reality, in lesions in you showing gene AD, very elements. a quite classically ThX different ThX skin Bacterial driven diseases disease, these colonization which both also thought of of driven IL-X elements. toll-like And ThXX both receptor in HS, also And you expression

than one indications pathophysiologically really common diseases think between in an prime IRAKX might with both And we targeting these suspect. so degrader. of probably And for therefore, more are there's those diseases

Nello Mainolfi

Great. Thanks, Jared.

our myself just and team to community, this don't whole appreciate engagement We've year. and the the today. from from know, joining say I had, I want of thanks, the we hundreds maybe So meetings to investors. from conclude, analysts for everybody,

in we is that So there appreciate doing. we're interest what

facts to in interested and you what of that Kymera. As we're follow we're know, about up are always We're excited you many the with available at understanding designs doing.

the that is build drugs our company can it. sky technology the it's capitalize responsibility that and to the limit for and think really on power of develop to the I really the

of hopefully, conferences we'll look some weeks. forward you, So to few you, the and next be we of December in where in all seeing you present at maybe

Operator

call. conference today's concludes This

disconnect. now may You

Kymera Therapeutics (KYMR) 3 Nov 222022 Q3 Earnings call transcript